Lamina clinic’s Post

At Asembia's AXS24 Summit today at 4 PM PT, PANTHERx Rare Pharmacy VP of Program Management, Austin Russian, joins other industry experts on a panel titled, “The Road to Specialty Pharmacy Network Selection.” This enlightening discussion promises to provide critical insights for specialty manufacturers to develop the appropriate criteria and processes to select their limited specialty pharmacy network. Learn more about how we help manufacturers of rare disease treatments better serve the patients who need them the most at https://lnkd.in/ecegXbsh

⚠️ FDA's Proposed Wound Dressing Rule Raises Serious Concerns ⚠️ In a recent BioWorld MedTech article, our firm's Mark DuVal weighs in on FDA's controversial draft rule aiming to increase regulation on wound dressings containing antimicrobial agents. Key Takeaways: 📌 FDA seems determined to push through the rule despite significant industry opposition during a 2016 advisory hearing. 📌 Many affected wound dressings contain long-used antimicrobials with a proven safe history, undermining FDA's antibiotic resistance claims. 📌 FDA lacks solid data supporting its stance on these products contributing to antibiotic resistance. 📌 Involving Congress is crucial to prevent the rule's implementation, which could severely restrict patient access to vital wound care products. Industry stakeholders like the Alliance of Wound Care Stakeholders and the American Professional Wound Care Association have also voiced grave concerns about the rule's potential impact. Out of 74 comments submitted, a staggering 56 firmly objected to the rule, further highlighting the widespread industry opposition. As FDA persists with this concerning proposal, it's imperative that we, as an industry, remain vigilant and proactive in advocating for our clients and their patients. Read the full article here:https://lnkd.in/gAZz6TnU We'd love to hear your thoughts on this critical issue. Comment below or reach out to us directly to discuss how we can work together to protect patient access to essential wound care products. #WoundCare #MedicalDevices #RegulatoryAffairs #PatientAccess

Calculating the platelet recovery percentage in PRP. Another real world example.... We drew 60cc of blood....for the clinical application our target was 3cc of PRP and hoping to get to 5 billion platelets. The initial WBC was 3.2 The PRP WBC was 5.7 The initial platelet count was 289 The PRP platelet count was 1877. We hit our target of 3cc and 5.6 Billion platelets despite a very very low platelet recovery % with the protocol we used for this one case!

🌟 Say goodbye to nausea with Vomtrin ! 🌟 At PAX Pharma, we're proud to offer this breakthrough medication to help you conquer those queasy moments. Whether it's motion sickness, chemotherapy-induced nausea, or post-operative discomfort, Vomtrin is here to bring relief. Trust PAX Pharma for your wellness needs. #Vomtrin #PAXPharma #ReliefFromNausea

Abiomed Recalls All Impella Left Sided Blood Pumps for Risk of Motor Damage After Contact with Transcatheter Aortic Valve Replacement (TAVR) Stent Abiomed is recalling the Impella Intravascular Left Sided Blood Pumps because the pump’s Instructions for Use (IFU) do not adequately address precautions to take when treating patients who have undergone transcatheter aortic valve replacement (TAVR). The IFU lacks guidance to clinicians on how to manage use of Impella in patients with TAVR and fails to describe how the issue may present if an Impella interacts with TAVR. There is a potential risk that the Impella motor housing may come into contact with the distal stent of a transcatheter aortic valve replacement (TAVR). The contact may damage or destroy the motor’s impeller blades. The damaged Impella system may have reduced blood flow or pump stop, which may delay therapy or fail to provide enough support to the patient. This could be life threatening in people who require high levels of support. There is also a risk that pieces of the broken blades could enter the patient’s bloodstream. Please be aware, this recall is a voluntary correction, not a product removal. The U.S. Food and Drug Administration (FDA) has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries, serious health consequences, or death.

An article in Fortune, published Aug 13, states: "Nearly 6 million prescriptions for the class of drugs that include Wegovy and Ozempic were written between January and May in the U.S. for people who don’t have diabetes..." ⁠ (Register to join our Virtual Panel Discussion about this Wednesday Aug 23 at 12 PM EST (recording available after the live session): https://lnkd.in/g7fN3d5u ) ⁠ Therefore the problems with side effects, such as the delayed gastric emptying creating potentially fatal pulmonary aspirations during surgical procedures, are happening more frequently, with little to no education to patients and providers.⁠ ⁠ This, and much more, will be discussed during our upcoming event: Medications Panel: What weight-inclusive providers need to know about semaglutide and GLP-1 agonists, featuring Dr. Erin Knopf, MD, CEDS, Rebecca Berens, MD, Erin Ebert, LCSW-S and Lauren Newman RDN CDCES! ⁠

MORPh Training and Clinical Services - July 5th Respiratory Conference - learn about what’s new in Respiratory BOOK NOW for this face to face event in Cardiff https://lnkd.in/eQDKcgA5 Extended Agenda includes What’s new in Asthma and COPD Update on current Guidance including MART and AIR inhaler techniques - practical workshop Patient counselling and patient support LIVE Demonstration of Spirometry & FeNO and a guide to interpretations

Tales from the counter (with access to an HIE): received eprescription for renewal of Januvia 100 mg this morning. Thought “patient is older, should check kidney function.” Signed into UHIN CHIE, located most recent BMP for the patient - GFR of 31, sent RxChange request via Surescripts for Januvia 50 mg and recommended new BMP draw. Time spent- ~5 minutes. Incredible how efficient and effective #pharmacists can be if we have access to the right data.  creatinine levels should be included on escript with all rxs for >65 yo just like height, weight and BP are sent now.

#Ozempic and #Rybelsus are both FDA-approved for #type2diabetes not #obesity, but both cause #weightloss. What is the #difference? Heidi Borst from Forbes interviewed our Chief Medical Officer, Leon Igel, MD, FACP, FTOS, DABOM about the two #medications. You can read the article here to learn more. Thanks Julianne Roseman and Plug and Play. Intellihealth https://lnkd.in/e5xXJyTD